A first in human study of alpha-synuclein-PET tracers for Parkinson's disease
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2018
Price : $35 *
At a glance
- Drugs Alpha-synuclein-PET tracers (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man
- 15 Nov 2018 According to an AC Immune media release, the company has been awarded a follow-up grant from The Michael J. Fox Foundation to facilitate the execution of this trial. The study will commence in Q1 of 2019.
- 02 May 2018 According to an AC Immune media release, data were presented at he AAT-AD/PD Focus Meeting 2018 on March 15, 2018.
- 21 Mar 2018 New trial record